Mereo BioPharma Group plc
Last updated September 27, 2026
Organization details
- Legal name
- Mereo BioPharma Group plc
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- United Kingdom
- Headquarters city
- London
- Headquarters country
- United Kingdom
- Fiscal year end
- December
- Ticker symbol
- MREO
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001719714
Board of directors
-
Anders Ekblom · DirectorSince 2024
-
Annalisa Jenkins · DirectorSince 2024
-
Daniel Shames · DirectorSince 2024
-
Deepika Pakianathan · DirectorSince 2024
-
Denise Scots-Knight · Director · Chief Executive OfficerSince 2024
-
Jeremy Bender · DirectorSince 2024
-
Justin Hunter Roberts · DirectorSince 2024
-
Marc J. Yoskowitz · DirectorSince 2024
-
Michael S. Wyzga · DirectorSince 2024
-
Pierre Jacquet · DirectorSince 2024
Chief executives
Denise Scots-Knight
· Chief Executive Officer
Dates unknown
Board connections
5 of this board's directors also sit on 11 other boards.
- via Jeremy Bender
- via Jeremy Bender
- via Annalisa Jenkins
- via Denise Scots-Knight
- via Deepika Pakianathan
- via Michael S. Wyzga
- via Deepika Pakianathan
- via Annalisa Jenkins
- via Annalisa Jenkins
- via Michael S. Wyzga
- via Michael S. Wyzga
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 13, 2024 | Denise Scots-Knight Director, Officer (Chief Executive Officer) | Open-market sale | −60,046 | $4.22 | $253,394 |
| Sep 13, 2024 | Lewicki John A. Officer (Chief Scientific Officer) | Open-market sale | −10,937 | $4.22 | $46,154 |
| Sep 13, 2024 | Sermon Charles Officer (General Counsel) | Open-market sale | −20,946 | $4.22 | $88,392 |
| Sep 13, 2024 | Fox Christine Ann Officer (Chief Financial Officer) | Open-market sale | −19,158 | $4.22 | $80,847 |
| Sep 13, 2024 | Hughes-Wilson Alexandra Officer (See Remarks) | Open-market sale | −16,304 | $4.22 | $68,803 |
| Sep 13, 2024 | Hughes-Wilson Alexandra Officer (See Remarks) | Open-market sale | −84,008 | $4.22 | $354,514 |
| Sep 12, 2024 | Denise Scots-Knight Director, Officer (Chief Executive Officer) | Open-market sale | −28,611 | $4.47 | $127,891 |
| Sep 12, 2024 | Lewicki John A. Officer (Chief Scientific Officer) | Open-market sale | −5,212 | $4.47 | $23,298 |
| Sep 12, 2024 | Sermon Charles Officer (General Counsel) | Open-market sale | −9,980 | $4.47 | $44,611 |
| Sep 12, 2024 | Fox Christine Ann Officer (Chief Financial Officer) | Open-market sale | −9,128 | $4.47 | $40,802 |
| Sep 12, 2024 | Hughes-Wilson Alexandra Officer (See Remarks) | Open-market sale | −7,769 | $4.47 | $34,727 |
| Sep 12, 2024 | Hughes-Wilson Alexandra Officer (See Remarks) | Open-market sale | −40,029 | $4.47 | $178,930 |
| Sep 11, 2024 | Sermon Charles Officer (General Counsel) | Option exercise | +65,600 | — | — |
| Sep 11, 2024 | Fox Christine Ann Officer (Chief Financial Officer) | Option exercise | +60,000 | — | — |
| Sep 11, 2024 | Lewicki John A. Officer (Chief Scientific Officer) | Option exercise | +46,000 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.